Staphylococcus (e.g., Staphylococcus Aureus, Etc.) Patents (Class 424/243.1)
  • Patent number: 10675340
    Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: June 9, 2020
    Assignee: Evaxion Biotech ApS
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Patent number: 10314916
    Abstract: An object of the present invention is to provide a low-cost and safe approach to efficient delivery of a substance to phagocytes. In particular, the present invention relates to a carrier for delivery of a substance to phagocytes, the carrier comprising a lactic acid bacterium and/or an extract thereof.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: June 11, 2019
    Assignee: House Wellness Foods Corporation
    Inventors: Yoshitaka Hirose, Shinji Murosaki, Yoshihiro Yamamoto
  • Patent number: 10076556
    Abstract: Methods of inhibiting or reducing tumor metabolism and growth are disclosed. A composition containing oxygen scavenging membrane fragments is administered within a tumor to create a hypoxic environment. This interferes with tumor growth and metabolism, and can lead to tumor death.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 18, 2018
    Assignee: OXYRASE, INC.
    Inventor: James C. Copeland
  • Patent number: 9534022
    Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: January 3, 2017
    Assignee: NovVac APS
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Patent number: 9474806
    Abstract: The invention relates to the compositions of synthetic oligo-?-(1?6)-2-amino-2-deoxy-D-glucopyranosides conjugated to carriers, and methods for making and use same.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: October 25, 2016
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Gerald B. Pier, Nikolay Nifantiev, Yury Tsvetkov, Marina Gening
  • Patent number: 9289481
    Abstract: The present invention features incapacitated whole-cell bacterial immunogenic compositions and methods of their production, which compositions are useful to deliver antigens in a manner resembling the live infectious organism in terms of elicitation of a robust immune response, but with reduced risk or no risk of disease. The compositions of the invention are produced by rendering a bacterium bacteriostatic through expression of a recombinant promoter in the bacterial cell, which promoter can be operably linked to a polynucleotide encoding a recombinant gene product. In one embodiment, where the bacterium is a gram negative host, the recombinant gene product provides for reduced toxicity of LPS. In one embodiment, the gene product is a bacteriophage protein, such as endolysin, holin, or ndd.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: March 22, 2016
    Assignee: Gangagen, Inc.
    Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
  • Patent number: 9205142
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunization. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: December 8, 2015
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Fabio Bagnoli, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
  • Patent number: 9091689
    Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: July 28, 2015
    Assignee: New York University
    Inventors: Victor J. Torres, Francis Alonzo, III
  • Patent number: 9085631
    Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acid encoding the proteins and methods of use of these nucleic acids.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: July 21, 2015
    Assignee: Nov Vac APS
    Inventors: Niels Iversen Møller, Andreas Mattsson
  • Patent number: 9060965
    Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: June 23, 2015
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Paolo Costantino, Maria Rosaria Romano, Francesco Berti
  • Publication number: 20150147328
    Abstract: The present invention relates to a vaccine composition for preventing staphylococcus aureus infection containing, as an active ingredient, a ribitol-phosphate which has been modified only by a ?-configuration in N-Acetylglucosamine (GlcNAc), a repeating unit of the ribitol-phosphate, or a wall teichoic acid (WTA) containing the repeating unit. The composition according to the present invention contains a coupling motif (an epitope) for an anti-WTA antibody, and thus can be effectively used as a vaccine composition or to prevent staphylococcus aureus infection by generating anti-WTA antibody.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 28, 2015
    Applicants: MOGAM BIOTECHNOLOGY INSTITUTE, PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Bok Luel Lee, Kurokawa Kenji, Dong-Jun Jung, Jang-Hyun An, Yu-Jin Jeon, Na Hyang Kim, Takahashi Kazue, Eunmi Kim, Dong Ho Ahn
  • Patent number: 9040057
    Abstract: A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of S. pneumoniae strains CGSP14, wherein administration of the recombinant pneumococcal neuraminidases elicits an immune response to S. pneumoniae, and treats the subject. In one embodiment, the method further includes a step of adding adjuvants to enhance the immune response. The method also includes a step of using passive antibodies, wherein said passive antibodies are anti-neuraminidase antibodies generated from neuraminidases-immunized humanized animals: NanA, NanB, and NanC. Meanwhile, this invention also provides a method for the molecular diagnosis of pneumococcal infection.
    Type: Grant
    Filed: September 25, 2011
    Date of Patent: May 26, 2015
    Assignee: CHANG GUNG MEDICAL FOUNDATION, LINKOU BRANCH
    Inventors: Cheng-Hsun Chiu, Rajendra Prasad Janapatla, Chyi-Liang Chen, Mei-Hua Hsu, Hsiu-Ling Chen, Chung-Tsui Huang, Hsin-Ju Chang, Wan-Ting Liao
  • Patent number: 9005579
    Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: April 14, 2015
    Assignees: Contrafect Corporation, The Rockfeller University
    Inventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
  • Patent number: 8974799
    Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerizing the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidizing the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidized saccharide residue; and (c) coupling the oxidized saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: March 10, 2015
    Assignee: Novartis AG
    Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
  • Publication number: 20150044251
    Abstract: Adding stabilizing additives to immunogenic compositions is effective in enhancing antigen stability. Suitable stabilizing additives include EDTA (ethylenediaminetetraacetic acid), sucrose, arginine, protease inhibitors, glycerol and/or citrate.
    Type: Application
    Filed: December 21, 2012
    Publication date: February 12, 2015
    Inventors: Mario Contorni, Lorenzo Tarli, Anna Coslovi, Michele Sotgiu
  • Patent number: 8945588
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve an Ebh antigen.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: February 3, 2015
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim
  • Patent number: 8936791
    Abstract: A method for in vitro diagnosis of Staphylococcus aureus producing Panton-Valentine Leukocidin (PVL), using a biological sample derived from an individual liable to be colonized by or infected with Staphylococcus aureus, wherein the diagnosis is carried out by detection of PVL using a routine immunological test, and the biological sample is pretreated in order to denature the PVL.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: January 20, 2015
    Assignees: Biomerieux, Intstitut National de la Sante et de la Recherche Medicale (Inserm), Universite Claude Bernard Lyon 1 (UCBL)
    Inventors: Cedric Badiou, Jerome Etienne, Gerard Lina, Catherine Ratat
  • Patent number: 8933218
    Abstract: The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: January 13, 2015
    Assignee: GlaxoSmithKline Biologicals s.a.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Tomas Maira-Litran
  • Patent number: 8920815
    Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: December 30, 2014
    Assignee: Immunology Laboratories, Inc.
    Inventors: Jiri Pillich, John C. Balcarek
  • Publication number: 20140377309
    Abstract: The present invention relates to the field of immunology. The present invention provides agonists and antagonists of Toll-like receptor (TLR) 13. In particular, the present invention provides TLR13 activating and inhibiting nucleic acids, and provides such nucleic acids for use as pharmaceutical agents. The present invention further provides in vitro methods using such nucleic acids.
    Type: Application
    Filed: February 8, 2013
    Publication date: December 25, 2014
    Inventors: Carsten Kirschning, Stefan Bauer, Hubertus Hochrein
  • Patent number: 8911748
    Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 16, 2014
    Assignee: Boise State University
    Inventor: Juliette Tinker
  • Patent number: 8889145
    Abstract: The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: November 18, 2014
    Assignee: Wyeth LLC
    Inventors: Annaliesa Anderson, Viliam Pavliak, Kathrin Ute Jansen, Ingrid Lea Scully, Steven Morris Baker, Jasdeep Singh Nanra, Ellen Murphy, Bruce Arthur Green, Mark Edward Ruppen, Yekaterina Timofeyeva
  • Patent number: 8889150
    Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: November 18, 2014
    Assignee: SOCPRA—Sciences et Génie, s.e.c.
    Inventors: Francois Malouin, Marianne Allard, Christian Lebeau Jacob, Brian Geoffrey Talbot, Daniel Scholl, Pierre Lacasse, Moussa Sory Diarra, Celine Ster
  • Publication number: 20140314810
    Abstract: The invention provides methods of producing vaccines directed against methicillin-resistant Staphylococcus aureus (MRSA) or Venezuelan equine encephalitis virus (VEEV), with the methods comprising culturing, harvesting and/or suspending the MRSA or VEEV in the presence of a radiation-protective composition and irradiating the MRSA with a dose of radiation sufficient to render the MRSA or VEEV replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide.
    Type: Application
    Filed: November 1, 2012
    Publication date: October 23, 2014
    Applicant: United States Department of Health and Human Services
    Inventors: Michael Daly, Elena K Gaidamakova, Ian A. Myles, Patricia A. Valdez, Sandip K. Datta
  • Publication number: 20140302120
    Abstract: The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.
    Type: Application
    Filed: June 19, 2014
    Publication date: October 9, 2014
    Inventors: Dennis A. Carson, Howard B. Cottam, Wolfgang Wrasidlo, Christina C.N. Wu, Gregory A. Daniels
  • Patent number: 8840906
    Abstract: Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing HIa to provide immunoprotection against S. aureus pneumonia. In certain aspects the invention includes a HIa with reduced toxicity, represented by a recombinant mutant form of HIa (HlaH35L) in which histidine 35 is converted to leucine, which can be used to abrogate the productive assembly of the toxin and protect a subject from staphylococcal pneumonia.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: September 23, 2014
    Assignee: The University of Chicago
    Inventors: Juliane Bubeck-Wardenburg, Olaf Schneewind, Brook Ragle
  • Patent number: 8834898
    Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: September 16, 2014
    Assignee: Boise State University
    Inventor: Juliette Tinker
  • Publication number: 20140248273
    Abstract: The present invention relates to the field of vaccinology, especially of vaccines against Staphylococcus aureus, for both human and veterinary application. In particular the invention relates to a Staphylococcal superantigen-like 3 (SSL3) protein or its homolog, an immunogenic fragment of either protein, for use in a vaccine against S. aureus. In addition the invention relates to vaccines, methods, and medical uses of these proteins.
    Type: Application
    Filed: September 7, 2012
    Publication date: September 4, 2014
    Inventors: Jos van Strijp, Carla de Haas, Paul Vermeij, Bart Bardoel
  • Patent number: 8821894
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: September 2, 2014
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim
  • Patent number: 8808699
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant or an antibody directed thereto.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: August 19, 2014
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Alice Cheng, Dominique M. Missiakas, Hwan Keun Kim
  • Patent number: 8758765
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve an EsaC polypeptide.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: June 24, 2014
    Assignee: The University of Chicago
    Inventors: Dominique Missiakas, Olaf Schneewind, Monica Burts
  • Patent number: 8753650
    Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: June 17, 2014
    Assignee: Novartis AG
    Inventors: Vega Masignani, Marirosa Mora, Maria Scarselli
  • Patent number: 8747864
    Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: June 10, 2014
    Assignee: Novartis AG
    Inventors: Vega Masignani, Marirosa Mora, Maria Scarselli
  • Publication number: 20140141041
    Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
    Type: Application
    Filed: December 30, 2013
    Publication date: May 22, 2014
    Applicant: VAXIN INC.
    Inventor: De-Chu C. Tang
  • Patent number: 8715687
    Abstract: The present invention relates to ClfA polypeptides wherein amino acid Y474 or an amino acid adjacent to Y474 is mutated such that fibrinogen binding activity is decreased compared to an equivalent ClfA polypeptide without mutation of Y474 or an amino acid adjacent to Y474 as well as immunogenic compositions, vaccines, processes and uses of such mutated ClfA polypeptides.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: May 6, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Guy Dequesne, Sophie Marie Jeanne Valentine Germain
  • Patent number: 8715688
    Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 6, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitte Tempelmaier, Claire M. Fraser, Steven Gill
  • Patent number: 8709436
    Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: April 29, 2014
    Assignee: Epitopix, LLC.
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
  • Patent number: 8703148
    Abstract: The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine group on PNAG to form a PNAG conjugate. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising PNAG and Type 5 and/or 8 capsular polysaccharides are also described.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: April 22, 2014
    Assignee: GlaxoSmithKline Biologicals S.A
    Inventors: Ralph Leon Biemans, Philippe Denoel, Pierre Duvivier, Tomas Maira-Litran, Jan Poolman
  • Patent number: 8691242
    Abstract: The invention relates to an antigenic polypeptide referred to as DivlB and variants thereof, vaccines comprising said polypeptide and the use of the vaccine in protecting subjects from microbial infection.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: April 8, 2014
    Assignee: Absynth Biologics Limited
    Inventors: Jorge Garcia Lara, Simon Foster
  • Publication number: 20140093536
    Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
    Type: Application
    Filed: July 30, 2013
    Publication date: April 3, 2014
    Inventors: Jiri Pillich, John C. Balcarek
  • Publication number: 20140093539
    Abstract: Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 ?g.
    Type: Application
    Filed: December 5, 2013
    Publication date: April 3, 2014
    Applicant: Protalex, Inc.
    Inventor: Paul Mann
  • Patent number: 8679505
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunization. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: March 25, 2014
    Assignee: Novartis AG
    Inventors: Fabio Bagnoli, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
  • Publication number: 20140072556
    Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acid encoding the proteins and methods of use of these nucleic acids.
    Type: Application
    Filed: April 3, 2012
    Publication date: March 13, 2014
    Applicant: Nov Vac APS
    Inventors: Niels Iversen Møller, Andreas Mattsson
  • Patent number: 8663654
    Abstract: The invention relates to compositions of the capsular polysaccharide/adhesin (PS/A) of staphylococci. The PS/A may be isolated or synthesized and includes various modifications to the structure of native PS/A based on the chemical characterization of PS/A. The invention also relates to the use of the PS/A as a vaccine for inducing active immunity to infections caused by Staphylococcus aureus, S. epidermidis, other related coagulase-negative staphylococci and organisms carrying the ica (intracellular adhesin) locus, and to the use of antibodies directed to PS/A for inducing passive immunity to the same class of infections.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: March 4, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Gerald B. Pier, Julia Wang, David McKenney
  • Publication number: 20140050732
    Abstract: The present invention relates a combination for use in the treatment and/or prevention of mastitis containing i) an agonistic anti-CD40 monoclonal antibody or a CD40 ligand or a vector coding for the anti-CD40 antibody or a vector coding for the CD40L; and ii) inactivated or attenuated bacteria selected from the group consisting of Staphylococcus, Streptococcus, Listeria or Escherichia.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 20, 2014
    Inventors: Fabrice Bureau, Hughes Wallemacq, Philippe Boutet, Pierre Lekeux, Laurence Fievez, Julien Pujol
  • Patent number: 8647640
    Abstract: The present invention provides a novel immunogenic composition, vaccine and methods for making and using the immunogenic composition and vaccine. The immunogenic composition is capable of providing an immune response and/or a protective immunity into subjects, preferably mammals, against microorganism-associated disease. The immunogenic composition includes one or more extracellular proteins isolated from a microorganism capable of providing an immune response and/or a protective immunity into subjects against microorganism-associated disease. The isolated extracellular proteins range in molecular weight from about 10,000 Da to about 220,000 Da. Suitable microorganisms may include members of the genus Salmonella, Listeria, Pseudomonas, Staphylococcus, and Vibrio. Kits are also encompassed for detection, diagnosis and prevention of microorganism-associated disease.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: February 11, 2014
    Inventor: Richard E. Cowart
  • Publication number: 20140037716
    Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.
    Type: Application
    Filed: March 19, 2012
    Publication date: February 6, 2014
    Inventor: Alexandre Eduardo Nowill
  • Patent number: 8632783
    Abstract: Staphylococcus aureus Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunization are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens, including Hla polypeptides having deletions, insertions, and/or mutations, are identified for use in immunization. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: January 21, 2014
    Assignee: Novartis AG
    Inventors: Fabio Bagnoli, Luigi Fiaschi
  • Patent number: 8623371
    Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagonosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: January 7, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Michael Otto, Stanislava Kocianova
  • Publication number: 20130295137
    Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
    Type: Application
    Filed: July 3, 2013
    Publication date: November 7, 2013
    Inventors: Jiri Pillich, John C. Balcarek